Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2018

View Archived Issues

Sumitomo Dainippon and JCR sign CNS license agreement

RV3-BB administered at birth or to infants prevents severe rotavirus gastroenteritis

Merrimack initiates phase II trial of MM-121 in postmenopausal metastatic breast cancer

Xencor and Selexis sign four commercial license agreements

ALDA-1 ameliorates myocardial injury after hemorrhagic shock in rats

IL-23 mediates resistance to anti-TNF therapy in Crohn's disease

Serum MMP-9 levels linked to relapse in quiescent small bowel Crohn's disease

TLR1 gene variation tied to melioidosis and increased hospital mortality

FDA grants priority review to lusutrombopag NDA

UCB patents MAPT-targeting pyrrolo-dipyridine derivatives

Arising International divulges new PD-1/PD-L1/CD80 interaction inhibitors

Daiichi Sankyo submits regulatory filing for esaxerenone in Japan

Medshine Discovery presents novel S1P1 receptor agonists

New phase I trial evaluates safety and immunogenicity of Zika virus vaccine candidate VLA-1601

Eli Lilly patents novel BACE1 inhibitors

FDA awards orphan drug designation to EHP-102 for Huntington's disease

Genentech and Roche present new TRPA1 antagonists

U.S. sites join international trials of MEDI-3902 and MEDI-4893

FDA grants orphan drug designation to taurolidine for neuroblastoma

AbbVie initiates phase II trial of ABT-165 plus FOLFIRI in colorectal cancer

Durect initiates phase IIa trial of DUR-928 in primary sclerosing cholangitis

Bavarian Nordic collaborates to study CV-301 with durvalumab in colorectal and pancreatic cancers

Enrollment open in phase I trial of MK-5890

ObsEva reports topline results from phase III trial of nolasiban in IVF

FDA approves Verzenio as initial treatment for advanced breast cancer

ARCA reports phase IIb study results for Gencaro in atrial fibrillation

DBV reports preliminary results from phase II portion of MILES study with Viaskin Milk

RaQualia completes phase I trial of RQ-00310941

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....